Loading clinical trials...
Loading clinical trials...
Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study
Conditions
Interventions
Radiotherapy for targeted lesions and PD-1 antibody
Locations
1
China
Lei Li
Beijing, Beijing Municipality, China
Start Date
March 26, 2022
Primary Completion Date
September 26, 2022
Completion Date
March 26, 2023
Last Updated
April 11, 2022
NCT07138755
NCT07339774
NCT07332000
NCT06951646
NCT06719440
NCT07325721
Lead Sponsor
Lei Li
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions